Category: ~$11.5B

  • Merck to Acquire Acceleron for ~$11.5B

    Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected to close in Q4’21 The acquisition will strengthen Merck’s cardiovascular pipeline. Acceleron’s sotatercept is currently in P-III trials & has the potential to improve short-term […]